Davide Pisu, PhD

Assistant Professor of Microbiology and Immunology

(985)871-6529
18703 Three Rivers Road, Covington LA 70433
Davide Pisu

Education & Affiliations

PhD in BioMedicine, University of Padua, 2015
MS in Biotechnology for Human Health, University of Siena, 2010
BS in Biotechnology, University of Sassari, 2008

Research

Research Interests
  • Host–pathogen interactions during early Mycobacterium tuberculosis infection, including determinants of bacterial permissiveness and control.
  • Lung macrophage heterogeneity, ontogeny, and functional state transitions in health, tuberculosis, and HIV–TB co-infection.
  • Granuloma formation and evolution, with emphasis on immune cell organization and function within infected lung tissue.
  • Macrophage–T cell interactions and their role in shaping local and systemic immune responses during mycobacterial infection.
  • Transcriptional, epigenetic, and chromatin-level regulation of immune responses to intracellular pathogens.
  • Use of non-human primate and murine models, combined with single-cell and multimodal genomic approaches, to study infectious disease pathogenesis.
     
Research Programs
 

Macrophage heterogeneity in tuberculosis infection outcomes

Tuberculosis is initiated and sustained within lung macrophages, yet these cells are highly heterogeneous in origin, function, and permissiveness to Mycobacterium tuberculosis. Our research focuses on how distinct alveolar and recruited macrophage subsets shape early infection outcomes, including bacterial survival, immune activation, and progression toward protective or permissive disease states. We investigate how macrophage ontogeny, activation state, and transcriptional and epigenetic programs determine differential control of M. tuberculosis during the earliest stages of infection, before adaptive immunity is fully established.

HIV–TB co-infection and macrophage dysfunction in the lung

HIV infection dramatically increases the risk of active tuberculosis, even in individuals receiving antiretroviral therapy. A major focus of our work is to define how HIV alters macrophage biology in the lung and compromises early control of M. tuberculosis. We study how HIV-driven immune dysregulation affects alveolar macrophage function, macrophage–T cell interactions, and inflammatory balance during TB infection, with particular emphasis on mechanisms that destabilize granuloma integrity and promote disease progression in co-infected hosts.

Granuloma formation and immune cell interactions

Granulomas represent the central pathological and immunological structures of tuberculosis, yet the cellular interactions that govern their formation and function remain poorly defined. Our research examines how macrophages organize, maintain, and remodel granulomas, and how their interactions with T cells and other immune populations influence local immune responses and bacterial control. By studying granulomas at early and intermediate stages of infection, we aim to define how immune cell composition and spatial organization determine protective versus pathogenic outcomes.

Host–pathogen determinants of tuberculosis pathogenesis in animal models

We use complementary murine and non-human primate models of tuberculosis to identify host and bacterial factors that govern M. tuberculosis pathogenesis in vivo. These models provide access to early infection events and lung tissue compartments that are not readily accessible in humans. By integrating in vivo infection models with single-cell and multimodal genomic approaches, we investigate bacterial gene requirements, host immune states, and their intersection within defined macrophage populations to understand mechanisms of TB pathogenesis and persistence.

Contributions

Key Publications

Russell DG, Simwela NV, Mattila JT, Flynn J, Mwandumba HC, Pisu D. How macrophage
heterogeneity affects tuberculosis disease and therapy. Nat Rev Immunol. 2025 May;25(5):370-384.
PubMed PMID: 39774813.    

Pisu D, Johnston L, Mattila JT, Russell DG. The frequency of CD38(+) alveolar macrophages
correlates with early control of M. tuberculosis in the murine lung. Nat Commun. 2024 Oct 2;15(1):8522.
PubMed Central PMCID: PMC11447019.

Pisu D, Huang L, Narang V, Theriault M, Lê-Bury G, Lee B, Lakudzala AE, Mzinza DT, Mhango DV,
Mitini-Nkhoma SC, Jambo KC, Singhal A, Mwandumba HC, Russell DG. Single cell analysis of M.
tuberculosis phenotype and macrophage lineages in the infected lung. J Exp Med. 2021 Sep 6;218(9)
PubMed Central PMCID: PMC8302446.

Pisu D, Huang L, Grenier JK, Russell DG. Dual RNA-Seq of Mtb-Infected Macrophages In Vivo
Reveals Ontologically Distinct Host-Pathogen Interactions. Cell Rep. 2020 Jan 14;30(2):335-350.e4.
PubMed Central PMCID: PMC7032562.

Pisu D, Provvedi R, Espinosa DM, Payan JB, Boldrin F, Palù G, Hernandez-Pando R, Manganelli R.
The Alternative Sigma Factors SigE and SigB Are Involved in Tolerance and Persistence to
Antitubercular Drugs. Antimicrob Agents Chemother. 2017 Dec;61(12) PubMed Central PMCID:
PMC5700316.

View Dr. Pisu's publications on PubMed.